Source 20240722_182811
Canonical Links
| item | link |
|---|
| Direct transcription | 20240722_182811 |
| Raw photo | data/raw/photos/20240722_182811.jpg |
| field | value |
|---|
| Page label | Page 498 of 504 |
| Navigation path | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dose finding > Delayed start design |
| Section | GBA-PD, GD, and α-Synuclein Pipeline |
| Uncertain spans | 3 |
| Embedded images | 0 |
| Related photos | 2 |
Headings
- GBA GT v2_GP sample-size tail, 20190423 Sclareol-NS imaging strategy 4-panel chart, Sample size calculation (proportion / Visions Pharmaceutical 2021 #1755 / Lundkya 2013), Innovative design / Interim analysis / β regression model / FDA-EMA principle, C-Path DAT Enrichment slide, Delayed start design (Liu-Seifert 2015 sketch), MEAN STRIATUM DAT vs AV133 table
- DAT Enrichment allows ~24% Reduction of Trial Size to Detect a Disease modifying Drug Effect with 80% Power (slide)
- Delayed start design
- MEAN STRIATUM DAT vs AV133
- Uncertain Spans
Wiki Coverage
Topic-level synthesis should link back to this source note or directly to the canonical transcription when making specific claims.